Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

[
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
[og_img]
https://www.investing.com/news/press-releases/nxera-pharma-notes-neurocrine-biosciences-presents-new-positive-data-from-phase-2-study-of-nbi1117568-in-adults-with-schizophrenia-at-american-society-of-clinical-psychopharmacology-2025-93CH-4069106


Investing.com